Epigenomics AG
EPGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6 |
| % Growth | -100% | -30.1% | -92.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $6 |
| % Margin | – | 83.2% | 75.3% | 97.8% |
| R&D Expenses | $0 | $0 | $6 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $4 | $4 |
| Other Operating Expenses | -$0 | $1 | $2 | $1 |
| Operating Expenses | $1 | $5 | $12 | $8 |
| Operating Income | -$1 | -$4 | -$12 | -$2 |
| % Margin | – | -1,231.2% | -2,484.7% | -37.9% |
| Other Income/Exp. Net | -$2 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$3 | -$4 | -$12 | -$2 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$3 | -$4 | -$12 | -$2 |
| % Margin | – | -1,315.8% | -2,479.2% | -39.1% |
| EPS | -3.96 | -5.23 | -14.78 | -4.33 |
| % Growth | 24.3% | 64.6% | -241.3% | – |
| EPS Diluted | -3.96 | -5.23 | -14.78 | -4.33 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | -$3 | -$4 | -$11 | -$2 |
| % Margin | – | -1,065.2% | -2,313.8% | -31.3% |